Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

NCT04361825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Durvalumab

Sponsor

Se-Hoon Lee

Collaborators

[object Object]